126 related articles for article (PubMed ID: 23489154)
1. Potential directions for drug development against galectin-7 in cancer.
St-Pierre Y; Biron-Pain K; Campion C; Lavoie G; Bouchard F; Couillard J
Expert Opin Drug Discov; 2009 Jun; 4(6):611-20. PubMed ID: 23489154
[TBL] [Abstract][Full Text] [Related]
2. Complex N-glycans are the major ligands for galectin-1, -3, and -8 on Chinese hamster ovary cells.
Patnaik SK; Potvin B; Carlsson S; Sturm D; Leffler H; Stanley P
Glycobiology; 2006 Apr; 16(4):305-17. PubMed ID: 16319083
[TBL] [Abstract][Full Text] [Related]
3. Phylogenetic analysis of the vertebrate galectin family.
Houzelstein D; Gonçalves IR; Fadden AJ; Sidhu SS; Cooper DN; Drickamer K; Leffler H; Poirier F
Mol Biol Evol; 2004 Jul; 21(7):1177-87. PubMed ID: 14963092
[TBL] [Abstract][Full Text] [Related]
4. Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin.
Vladoiu MC; Labrie M; Létourneau M; Egesborg P; Gagné D; Billard É; Grosset AA; Doucet N; Chatenet D; St-Pierre Y
Oncotarget; 2015 Dec; 6(38):40970-80. PubMed ID: 26543238
[TBL] [Abstract][Full Text] [Related]
5. Structural analysis of the human galectin-9 N-terminal carbohydrate recognition domain reveals unexpected properties that differ from the mouse orthologue.
Nagae M; Nishi N; Nakamura-Tsuruta S; Hirabayashi J; Wakatsuki S; Kato R
J Mol Biol; 2008 Jan; 375(1):119-35. PubMed ID: 18005988
[TBL] [Abstract][Full Text] [Related]
6. Thermodynamic binding studies of bivalent oligosaccharides to galectin-1, galectin-3, and the carbohydrate recognition domain of galectin-3.
Ahmad N; Gabius HJ; Sabesan S; Oscarson S; Brewer CF
Glycobiology; 2004 Sep; 14(9):817-25. PubMed ID: 15148296
[TBL] [Abstract][Full Text] [Related]
7. Unraveling galectin-1 as a novel therapeutic target for cancer.
Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Neuzillet C; Albert S; Raymond E; Faivre S
Cancer Treat Rev; 2014 Mar; 40(2):307-19. PubMed ID: 23953240
[TBL] [Abstract][Full Text] [Related]
8. Galectins as markers of aggressiveness of mouse mammary carcinoma: towards a lectin target therapy of human breast cancer.
Moiseeva EV; Rapoport EM; Bovin NV; Miroshnikov AI; Chaadaeva AV; Krasilshschikova MS; Bojenko VK; Bijleveld C; van Dijk JE; Den Otter W
Breast Cancer Res Treat; 2005 Jun; 91(3):227-41. PubMed ID: 15952056
[TBL] [Abstract][Full Text] [Related]
9. X-ray structure of a protease-resistant mutant form of human galectin-8 with two carbohydrate recognition domains.
Yoshida H; Yamashita S; Teraoka M; Itoh A; Nakakita S; Nishi N; Kamitori S
FEBS J; 2012 Oct; 279(20):3937-51. PubMed ID: 22913484
[TBL] [Abstract][Full Text] [Related]
10. Linear triazole-linked pseudo oligogalactosides as scaffolds for galectin inhibitor development.
Dussouy C; Kishor C; Lambert A; Lamoureux C; Blanchard H; Grandjean C
Chem Biol Drug Des; 2020 Oct; 96(4):1123-1133. PubMed ID: 32220037
[TBL] [Abstract][Full Text] [Related]
11. Intracellular galectins in cancer cells: potential new targets for therapy (Review).
Vladoiu MC; Labrie M; St-Pierre Y
Int J Oncol; 2014 Apr; 44(4):1001-14. PubMed ID: 24452506
[TBL] [Abstract][Full Text] [Related]
12. Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion.
Zou J; Glinsky VV; Landon LA; Matthews L; Deutscher SL
Carcinogenesis; 2005 Feb; 26(2):309-18. PubMed ID: 15528216
[TBL] [Abstract][Full Text] [Related]
13. Varied expression and localization of multiple galectins in different cancer cell lines.
Satelli A; Rao PS; Gupta PK; Lockman PR; Srivenugopal KS; Rao US
Oncol Rep; 2008 Mar; 19(3):587-94. PubMed ID: 18288388
[TBL] [Abstract][Full Text] [Related]
14. Galectin-3 inhibitors: a patent review (2008-present).
Blanchard H; Yu X; Collins PM; Bum-Erdene K
Expert Opin Ther Pat; 2014 Oct; 24(10):1053-65. PubMed ID: 25109359
[TBL] [Abstract][Full Text] [Related]
15. Galectin-3: an open-ended story.
Dumic J; Dabelic S; Flögel M
Biochim Biophys Acta; 2006 Apr; 1760(4):616-35. PubMed ID: 16478649
[TBL] [Abstract][Full Text] [Related]
16. An emerging role for galectins in tuning the immune response: lessons from experimental models of inflammatory disease, autoimmunity and cancer.
Rabinovich GA; Liu FT; Hirashima M; Anderson A
Scand J Immunol; 2007; 66(2-3):143-58. PubMed ID: 17635792
[TBL] [Abstract][Full Text] [Related]
17. Galectins in hematological malignancies.
Giordano M; Croci DO; Rabinovich GA
Curr Opin Hematol; 2013 Jul; 20(4):327-35. PubMed ID: 23695449
[TBL] [Abstract][Full Text] [Related]
18. Ligand interactions of the Coprinopsis cinerea galectins.
Walser PJ; Kües U; Aebi M; Künzler M
Fungal Genet Biol; 2005 Apr; 42(4):293-305. PubMed ID: 15749049
[TBL] [Abstract][Full Text] [Related]
19. Role of the carbohydrate recognition domains of mouse galectin-4 in oligosaccharide binding and epitope recognition and expression of galectin-4 and galectin-6 in mouse cells and tissues.
Marková V; Smetana K; Jeníková G; Láchová J; Krejciríková V; Poplstein M; Fábry M; Brynda J; Alvarez RA; Cummings RD; Maly P
Int J Mol Med; 2006 Jul; 18(1):65-76. PubMed ID: 16786157
[TBL] [Abstract][Full Text] [Related]
20. The N-terminal carbohydrate recognition domain of galectin-8 recognizes specific glycosphingolipids with high affinity.
Ideo H; Seko A; Ishizuka I; Yamashita K
Glycobiology; 2003 Oct; 13(10):713-23. PubMed ID: 12851289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
